Transplant cells a compatible brother mother improves survival of patients with myeloma.
Spain, 2011-September in the month of July, the Journal of Clinical Oncology journal echoed a study carried out by the team Doctor Bo Bjorkstrand of the Karolinska Institute, Sweden, from which was extracted to patients with multiple myeloma without attempting to improve much more with a followed by an allogeneic cell transplant Autologous stem cell transplantation a compatible brother, compared with an autologous transplant only.
The multicenter study carried out in Europe revealed that 60 months disease-free survival was significantly better in the group treated with autologous-allogeneic transplant (35 percent) than in people receiving only transplant autologous (18 percent).
The survival rate for both groups was 65 and 58 per cent, respectively. The study included 108 patients treated with combined transplantation and 249 treated with autologous transplantation only.
Chemotherapy in high doses with Autologous stem cell transplant is the treatment of first choice for patients with multiple myeloma of up to 65 years.
It is a study that sheds more light for a type of specific patients whom they may improve survival with a kind of different therapeutic approach.
About IVIDA
IVIDA is the Bank of lVI umbilical cord leading European in reproductive medicine with 22 clinics and presence in 8 countries. IVIDA offers a comprehensive service for preservation of umbilical cord, giving families retain the sample of the newborn in the public bank located at the headquarters in Madrid or in the private bank located at the headquarters of Lisbon. IVI, with more than 20 years in the service of the reproduction, IVIDA patients guarantees absolute control of the entire process, from the collection of the sample to the freezing of the same.
